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ABSTRACT 
Quality healthcare will be obtained by the adherence or the compliant behavior of the patient. Poor compliance has a major effect on the clinical 
consequences and the therapeutic effects of the dosage regimen. The present review is an effort to study the reported clinical studies and the 
referred conclusions. Studies show that poor compliance reduces the therapeutic efficacy of the dosage regimen to a certain degree. Poor or 
partial compliance may be due to several reasons, one of which is the behavioral patterns of the patients. Several studies report the methods to 
measure compliance so as to determine the effect of the compliance on the therapeutic efficacy. Compliant patients have the greater chances of 
obtaining the maximum benefits of the prescribed medication.  
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INTRODUCTION 
Poor patient compliance to a medication has major impact 
on the success of patient care, conduct and results of the 
clinical trials. Reported clinical studies suggest that poor 
compliance may result in increased possibilities of 
hospitalization in case of patients with hypertension,[1] and 
reduced improvements in hypercholesteremic patients,[2] 
and increased mortality rate in patients with acute 
myocardial infarction [3]. The possible effect of poor 
compliance includes less knowledge on the therapeutic 
efficacy of the medication. The enough magnitude of 
therapeutic effect due to poor compliance may show 
negative results of the clinical trials, where there are chances 
of positive response [4-7]. 
In other word if the patients have an accurate behavior with 
the physician or other health care services then he is said to 
be compliant. Poor compliance may include inattention to 
diet or workout plans, not having the dose in prescribed 
manner or having them at improper intervals of time, failure 
in refilling the prescriptions, irregular follow-up visits to the 
physician etc. The focus of this review is on compliance to 
medication regimens. 
Patient noncompliance may be due to several reasons. The 
simplest reason may be the forgetfulness tendency in case of 
non-symptomatic conditions such as hypertension. 
Alternatively, poor compliance may also be due to potential 
side-effects of the treatment, perception of the patient that 
the treatment would not cure the illness or personal belief 
on the health status. For example, a study on the elderly 
diabetic [8] patients when evaluated showed positive impact 
on the health in case of patients compliant to fasting blood 
sugar treatment when compared to the hospitalized 
alternates thus stating that an individual’s behavior can have 
a positive impact on the health status. Additional reasons for 
poor compliance include cost of the medication, reasoning of 
the patient or the complexity of the dose regimens. The 
latter two reasons are more common in case of elderly 
patients resulting in patient noncompliance. 
Measuring Compliance 
The general method for measuring compliance may include 
use of biological marker like plasma concentrations, urine 
assay which provide direct information from the patient. 
Another method may be counting the pills that give the 
count of the returned bottles. All these methods can be used 
for measuring compliance but each of the method has an 
inadequate effect which may be: 
1. Difference in measured compliance when two or more 
methods are evolved  
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2. Comparison to newer electronic methods to quantify 
compliance 
The limitations to the pill count method have been reported 
by several authors. [9, 10] 
For example, Pullar[9] et al assessed compliance by both the 
plasma concentration and pills count method on 225 
subjects. 204 of the subjects shoed a follow up visit. Out of 
which 161 of them showed compliant as their pill count was 
about 90%-109% indicating that the medication was 
properly followed. But 51 out of the 161 had doses and body 
weight plasma concentrations which was completely 
opposite to the pre-assumed results. Due to the large 
differences in the results of the two methods, pill count 
method for measuring compliance cannot be justified. The 
insufficient assessment of the compliance due to patient 
interview has been highlighted by reports such as that of 
Norell[11], that shows the measurement of compliance by 
four methods[12-15] one of which included patient interview 
and followed by other methods. The results were that the 
interview rates ranged from 12%-31% as compared to other 
methods which showed 32%-82%. In another study Caron, 
reported that most of the patients had taken only 47% of the 
medication and claimed to have taken 89%. 
In recent, years the use of microcircuitry which consists of 
microminiaturized chips for electronic monitoring of the 
patient compliance which assess the compliance from the 
date and time on which the medication has been dispensed. 
They provide the most accurate results. They have been 
attached to pill bottles, blister packs, aerosol containers etc. 
They also had an advantage over the traditional measures 
that overestimated the substantial compliance.  
Magnitude and Pattern of Poor Compliance 
Some studies reported good compliance rate up to 90%, 
while some documents often poor patient compliance. Good 
compliance may be associated with lesser side effects of the 
medication of acute and symptomatic diseases and with 
regular diagnoses [16]. In the Physicians Health Study [17] good 
compliance is the indication of the interested and highly 
educated medication system. However, compliance rate may 
also be low as up to 50% or less. Given that the traditional 
methods provide an overstated result of the substantial 
value, the magnitude of the problem may be inappropriate. 
While the number of doses taken may provide the simplest 
method for determining the compliance however it cannot 
deliver the real compliance as the pill count may also include 
doses taken at irregular intervals or during no dose period 
hence it is apparent that pill count method for measuring the 
compliance might be inadequate and the magnitude of the 
problem will not be recognized due to irregular drug taking 
pattern. 
The aspect and characteristic of the irregular dosing can be 
determined using electronic measuring devices. For 
example, the compliance tends to better with regular follow-
up visits to the physician. Thus, studies by Cramer et al [18] 
demonstrated that the compliance percent was 88% during 
the clinical visit while it was 73% in case of failure to visit 
the clinic. 
On other hand electronic devices helps to assess the 
compliance during “drug holiday” or the period during 
which the medication is not taken. Thus, De klerk et al 
studied the drug taking pattern in 65 subjects with 
ankylosing spondylitis prescribed with one day medication. 
While 80% of the doses were taken out of which only 61% 
were taken during the prescribed episode. Extra doses were 
taken on a 3.4% of the day while no dose was taken during 
19% of the days monitored. Among the nine subjects with 
extra dose percent about 81%-90%, four of them showed 
drug holiday period of 13 days. In kass et al study of 
glaucoma in 184 patients prescribed with four in a day 
pilocarpine eye drops, 24.5% of them showed one day per 
month no dose period while 52.7% showed five doses per 
day as the night dose was emitted. Thus, it is evident from 
the studies that a dose-friendly schedule aided to improve 
compliance. A potential influence of the irregular drug taking 
pattern was studied by Cramer et al in patients with 
epileptic seizures, showed seizure attacks during doses were 
missed. 
Another aspect of drug taking pattern on compliance is that 
it tends to reduce with time. Thus, in the Physicians Health 
Study the compliance rates were 95.3% which periodically 
reduced to 83.8% during the study itself. In the studies of 
the left ventricular dysfunction the compliance rates were 
80% during the first year, 745 during the second and 69% 
after three years.  
Effect of Poor Compliance on Sample Size 
Requirements in Clinical Trials 
When the patients do not comply with the prescribed 
medication regimen the therapeutic efficacy of the treatment 
tends to reduce. But in case of clinical trialsreduced efficacy 
will reduce the corresponding in between group differences 
thus resulting in the increase in the required sample size 
therefore the magnitude of the potential sample size is 
enlarged. [4-7] 
To measure the impact of the compliance on the sample size 
in clinical trials, Schechtman and Gordon [4] employedboth 
hypothetical and compliance data from Lipid Research 
Clinics (LRC) Coronary Prevention Trail. The hypothetical 
data showed that the goal was to compare the success rate in 
the clinical trial, and the placebo group showed up to 40% 
success rate and the treatment group showed 60% success 
rate which have taken the medication in the prescribed 
manner. A complaint patient is one who takes 80% of his 
medication and the success rate was found to be 90% in case 
of patients who took all of their pills.Using the data from the 
LCR trial it was stated that the cholesterol was reduced only 
by 32.55% in non-complaint patients and they received only 
40% of the therapeutic efficacy when compared to compliant 
patients. Table1. Shows the hypothetical data correlating the 
compliance and the dose size given by the studies of 
Schechtman and Gordon. Thus, the results indicated that if 
the compliance rate is 70% then the size requirement is 
1.84, if the rate is 60% then the size requirement is 2.14 and 
2.52 if the compliance rate is 50%. 
Table1. Effect of Poor Compliance on Sample Size 
Percentage of patient who comply  Sample size ratio 
90% 1.40 
80% 1.59 
70% 1.84 
60% 2.14 
50% 2.52 
40% 3.01 
 
In the LRC trail [2, 25], the treatment group was provided with 
a six daily packets of cholestyramine, a cholesterol lowering 
agent and was compared to the placebo group. The primary 
consequence was coronary heart disease mortality. If the 
compliance meant at least having five of the six daily packets 
then the compliance rate of placebo group was found to be 
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67.3% as compared to the 50.8% of treatment group thus 
the success rate of the placebo group was found to be 40% 
and that of the treatment group was found to be 90% as they 
had taken all the pills. The sample size ratio is the ratio 
between the required sample size and the corresponding 
patients who compliant to the sample size. 
Effect of Poor Compliance on the Clinical Status of 
the Patient  
Partial or poor compliance might be a hindrance if there is a 
causative relation between not taking the medication and 
the clinical status of the patient. On the other hand, it can be 
instinctively stated that a poor compliance of an effective 
medication can provide negative results of the clinical status. 
But at the same time the causative relation is dependent on 
the specificity of the case like the disease in question, the 
half life of the drug and the frequency of the medication. 
Moreover, poor compliance can also be associated to 
behavior pattern of the patient, hence the degree of 
negativity of the clinical consequences cannot be figured out, 
as the behavioral aspect correlates to poor compliance. In 
the Coronary Drug Project [19], patients compliant to 
clofibrate a lipid lowering agent, showed lower mortality 
rated compared to the non-complaint patients. The initial 
studies show that there is a correlation between the 
compliance and the mortality rate. But a further look at the 
study shows the same relation in case of the placebo data, 
hence the reduced mortality rate in the compliers was not 
only due to the medication but also that they were engaged 
in other activities that helped in improving their 
cardiovascular health. 
The note in the prior example is that it is not only poor 
compliance correlated to the degree of negativity of the 
clinical status of the patient but it is also dependent on the 
behavioral pattern of the patient under medication that may 
give negative clinical outcome. With these limitations we can 
illustrate the degree to which poor compliance may affect 
the clinical consequences.  
The literature contains a number of other studies that 
connects poor compliance with negative clinical compliance 
for example, increased hospitalization [20] in hypertension 
patients, seizures in epilepsy patients and increased 
coronary heart disease rate. The magnitude of the negative 
consequences is highlighted by the Joint National Committee 
on Evaluation which states that the higher rate of 
uncontrolled increased blood pressure is due to non-
compliance, by a 1984 conference on the therapeutic 
consequences of non-compliance, which suggested that 
125,000 annual death results from non-compliance in 
patients with cardio vascular disease. 
Improving Compliance in Clinical Trials 
Since poor compliance has a major affect on the clinical 
consequences and to the substantial efficacy of the 
treatment, it is possible that a number of researches are 
being carried out to enhance the compliance strategies. Such 
strategies can be broadly classified into two categories: 
1. Those that precede the initiation of the study 
therapy[2,5,22,24] 
2. Those that are implemented after randomization[2,25] 
Compliance enhancing strategies prior to randomization are 
mainly focused that the patients are more complaint who are 
being studied. This can be carried out by performing a 
formal or informal event before randomization. The informal 
event is carried out as in the LRC trial [21], where the patients 
are expected to attend the follow-up visits to the physician 
to assure that they compliant. If this event fails then it is 
evident that the patients are more likely to be non-compliant 
in future. A formal run-in also carried out before 
randomization which involves the potential patients who 
were compliant in the informal run-in. It involves placebo 
medication and the clinical visits. Patients who do not 
comply are excluded from the trial prior to randomization. It 
has been established that a run-in strategy has increased the 
power of the clinical trials. In general, it evident that the run-
in strategies have been beneficial when the poor compliance 
is associated with reduced clinical consequences.  
Compliance that involves randomization covers a broad 
range of activities that are discussed by many investigators 
[23]. These include educating people about the disease and 
the compliance, reducing the complexity of the dosing 
regimensthat would be appropriate to the patients schedule, 
establishing a positive relation between patient and the 
clinic, financial incentives, self-administered approaches 
such as proving calendars for remembering when the doses 
are to be taken, special packing like blister packing with 
instructions and encouraging the family members for 
supporting the patient. 
Compliance enhancing must be personalized to the patient 
and to the specific circumstances. Their achievement 
completely depends upon the inventiveness and the 
assurance of the health care provider. 
CONCLUSION 
Poor compliance is associated with both the patient and the 
medication regimen that may affect the effectiveness of the 
medication and also the conduct of the clinical trials. The 
magnitude of the compliance can be measured using 
electronic devices that provides the accurate results 
showing the percentage of compliance less than or equal to 
50% which is not uncommon. This may help in improving 
the treatment efficacy and reduce between group differences 
a situation that may lead to more numbers of clinical trials. 
Poor compliance also results in severe consequences of the 
clinical trial which have been demonstrated in several 
studies that include increased mortality rate, hospitalization 
rates, reduced control over hypertension, increased seizure 
attack in epileptic patients, increased rejection rates in 
transplant patients. Because of these consequences it gives 
opportunities to the researchers to develop strategies that 
would enhance the compliance in accordance with the 
prescribed schedule. 
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